Observational studyBMC cancer2025
Primary tumour resection in non-small cell lung cancer patients with pleural dissemination unexpectedly detected during operation: a two-centre retrospective cohort study.
Observational study in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06232967 (Long-term Outcome of Primary Tumor Resection in Non-Small-Cell Lung Cancer Patients With Dry Pleural Dissemination), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Long-term Outcome of Primary Tumor Resection in Non-Small-Cell Lung Cancer Patients With Dry Pleural Dissemination: A Multi-center Study
Who cites it
2 citing papers in PubMed.
- Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is no consensus regarding whether primary tumour resection (PTR) should be performed in non-small cell lung cancer (NSCLC) patients with unexpected pleural dissemination (PD) discovered at thoracotomy. MATERIALS AND
methodsConsecutive NSCLC patients with surgically confirmed PD were retrospectively enrolled from two high-volume centres between January 2016 and December 2023. Patients were divided into the primary tumour resection (PTR) and exploratory thoracotomy (ET) group. PTR included wedge resection, segmentectomy and lobectomy. Patients in the ET group received biopsy only. Propensity score matching (PSM) was used to reduce selection bias from confounding factors. Disease-specific survival (DSS) and progression-free survival (PFS) were analysed using the Kaplan‒Meier method, and comparisons were made using the log-rank test. Multivariate Cox regression analyses were performed to identify the independent prognostic factors.
resultsA total of 223 patients were identified: 167 (74.9%) in the PTR group and 56 (25.1%) in the ET group. The median follow-up time and median survival time (MST) were 39.0 months and 49.0 months, respectively. The MST for the ET and PTR groups were 44.0 and 60.0 months, respectively (HR 0.80, 95% CI 0.51-1.24; p = 0.3097). After PSM, there were no significant differences in terms of median disease-specific survival (DSS: 60.0 vs. 61.0 months, p = 0.3419) or progression-free survival (PFS: 30.0 vs. 47.0 months, p = 0.5471) between the two groups. Multivariate analysis revealed that smoking history and a tumour size ≥ 3 cm were independent risk factors for DSS and PFS, whereas targeted therapy was an independent protective factor.
conclusionOur results suggest that primary tumour resection does not improve long-term survival in NSCLC patients with unexpected PD discovered at thoracotomy. It is high time to re-evaluate the value of surgery for NSCLC patients with PD and avoid overtreatment, especially in the era of targeted therapy and immunotherapy.
trial registrationClinicalTrials.gov NCT06232967 (approval date: January 31, 2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.